Medical professionals observe that GLP-1 medications like Ozempic show promise for treating rheumatoid arthritis alongside ...

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

A trial investigating the ability of Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular issues has met ...

Research increasingly suggests that nutrient sequencing—eating macronutrients like protein and fiber in a particular ...

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

Patients with type 2 diabetes, treated with GLP-1 receptor agonists, show a decreased risk of being diagnosed with ...

Madrigal Pharmaceuticals Inc.’s long-awaited business development pact became reality by way of an exclusive global license ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality.

New research from scientists at the Marshall University Joan C. Edwards School of Medicine reveals that certain gut microbial ...